Emergent BioSolutions, Inc., enters into BioThrax agreement

Emergent BioSolutions, Inc., has entered into a material definitive agreement with Hollister-Stier Laboratories for filling services for its BioThrax vaccine.

Hollister-Stier will provide filling services for the BioThrax vaccine for a renewed five-year period starting on January 1. The agreement leaves the possibility for two added automatic two year renewal periods. The current filling agreement between the two parties expires on December 31.

Emergent BioSolutions, Inc., under terms of the agreement, is required to use Hollister-Stier for at least 75 percent of its BioThrax filling requirement.

Emergent BioDefense Operations Lansing LLC is the subsidiary of the company that is entering into the agreement.

BioThrax is currently the only vaccine for the prevention of anthrax that has been approved by the U.S. Food and Drug Administration. BioThrax has been given to over 2.5 million people to prevent infection.

Anthrax is classified by the Centers for Disease Control and Prevention as a potential bioterorrism agent. It is recognized as a Category A agent, posing the greatest possible threat for a bad effect on public health. Anthrax, if used as a bioterror agent, could also spread across a large area.

Emergent BioSolutions, Inc., is a multinational biopharmaceutical company attempting to protect human life by manufacturing, developing and commercializing immunobiotics, including therapeutics and vaccines.

Hollister-Stier is a contract manufacturer of sterile injectable and lyophilized products and a producer of allergenic extracts.